Treatment and biomarker testing patterns,treatment outcomes in a/m NSCLC with and without actionable genomic alterations

Trial Identifier: D133FR00204
Sponsor: AstraZeneca
Start Date: March 2024
Primary Completion Date: June 2026
Study Completion Date: June 2026
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations